MX2024003775A - Metodo de administracion segura del conjugado de fosfopeptido de tau. - Google Patents
Metodo de administracion segura del conjugado de fosfopeptido de tau.Info
- Publication number
- MX2024003775A MX2024003775A MX2024003775A MX2024003775A MX2024003775A MX 2024003775 A MX2024003775 A MX 2024003775A MX 2024003775 A MX2024003775 A MX 2024003775A MX 2024003775 A MX2024003775 A MX 2024003775A MX 2024003775 A MX2024003775 A MX 2024003775A
- Authority
- MX
- Mexico
- Prior art keywords
- safe administration
- tau phosphopeptide
- tau
- conjugate
- phosphopeptide conjugate
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0007—Nervous system antigens; Prions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/385—Haptens or antigens, bound to carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6068—Other bacterial proteins, e.g. OMP
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Rheumatology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163261793P | 2021-09-29 | 2021-09-29 | |
| PCT/US2022/077279 WO2023056369A1 (en) | 2021-09-29 | 2022-09-29 | Method of safe administration of tau phosphopeptide conjugate |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024003775A true MX2024003775A (es) | 2024-04-11 |
Family
ID=85783654
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024003775A MX2024003775A (es) | 2021-09-29 | 2022-09-29 | Metodo de administracion segura del conjugado de fosfopeptido de tau. |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20250049900A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4408864A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2024538615A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20240082368A (cg-RX-API-DMAC7.html) |
| CN (1) | CN118613496A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2022356435A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3233247A1 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2024003775A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2023056369A1 (cg-RX-API-DMAC7.html) |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102596236B (zh) * | 2009-07-30 | 2015-06-24 | 辉瑞疫苗有限责任公司 | 抗原性Tau肽及其用途 |
| TW202333768A (zh) * | 2017-10-25 | 2023-09-01 | 美商健生醫藥公司 | Tau胜肽之組成物及其用途 |
| MX2021012994A (es) * | 2019-04-24 | 2022-03-04 | Janssen Pharmaceuticals Inc | Administracion heterologa de vacunas tau. |
-
2022
- 2022-09-29 EP EP22877579.7A patent/EP4408864A4/en active Pending
- 2022-09-29 CA CA3233247A patent/CA3233247A1/en active Pending
- 2022-09-29 KR KR1020247013320A patent/KR20240082368A/ko active Pending
- 2022-09-29 CN CN202280078258.6A patent/CN118613496A/zh active Pending
- 2022-09-29 AU AU2022356435A patent/AU2022356435A1/en active Pending
- 2022-09-29 US US18/696,444 patent/US20250049900A1/en active Pending
- 2022-09-29 MX MX2024003775A patent/MX2024003775A/es unknown
- 2022-09-29 JP JP2024519447A patent/JP2024538615A/ja active Pending
- 2022-09-29 WO PCT/US2022/077279 patent/WO2023056369A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| AU2022356435A1 (en) | 2024-03-28 |
| CA3233247A1 (en) | 2023-04-06 |
| WO2023056369A1 (en) | 2023-04-06 |
| CN118613496A (zh) | 2024-09-06 |
| EP4408864A4 (en) | 2025-09-03 |
| EP4408864A1 (en) | 2024-08-07 |
| JP2024538615A (ja) | 2024-10-23 |
| KR20240082368A (ko) | 2024-06-10 |
| US20250049900A1 (en) | 2025-02-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2024004846A (es) | Compuesto tetraciclico que contiene nitrogeno, metodo de preparacion del mismo y uso medico del mismo. | |
| MX2024004921A (es) | Derivados de piperidinilindol, metodos de preparacion y usos medicinales de estos. | |
| MX2017014127A (es) | Conjugados proteina-polisacarido de estreptococo grupo b, metodos para producir conjugados, composiciones inmunogenas que comprenden conjugados y sus usos. | |
| MX2023007853A (es) | Compuesto heterociclico puenteado que contiene nitrogeno, metodo de preparacion y uso medico del mismo. | |
| CL2017002636A1 (es) | Composiciones que comprenden una combinación de un anticuerpo anti muerte programada 1 (pd-1) y otro anticuerpo. | |
| MX2018011348A (es) | Composiciones de extractos naturales y uso de los mismos para prevenir o tratar enfermedades. | |
| MX2020008445A (es) | Metodos para tratar el cancer con anticuerpos anti-pd-1. | |
| CO2019000214A2 (es) | Vacuna contra virus de bronquitis infecciosa | |
| AR095338A1 (es) | Método de tratamiento no tóxico para la abstinencia de drogas | |
| MX2020003756A (es) | Composiciones y metodos para obtener una respuesta inmune contra clostridium difficile. | |
| JP2018505882A5 (cg-RX-API-DMAC7.html) | ||
| AR120057A1 (es) | Composiciones neoantigénicas y usos de estas | |
| CL2021000882A1 (es) | Formulaciones y métodos para tratar las nauseas y vómitos inducidos por la quimioterapia. | |
| CL2019003533A1 (es) | Uso de vibegron para tratar vejiga sobreactiva. | |
| AR110800A1 (es) | MÉTODOS PARA AUMENTAR EN PLASMA SANGUÍNEO LA 2-DESOXIURIDINA (dUrd) Y LA INHIBICIÓN DE LA TIMIDILATO SINTASA | |
| CL2021002107A1 (es) | Triamtereno o nolatrexed para uso en el tratamiento de fenilcetonuria. | |
| MX2023004832A (es) | Método de administración segura del anticuerpo anti-tau. | |
| MX2015013115A (es) | Nuevos regimenes de dosificacion de celgosivir para el tratamiento de dengue. | |
| MX2025013493A (es) | Derivado de tiazol inhibidor, y metodo de preparacion del mismo y uso del mismo | |
| AR101901A1 (es) | Tratamiento de enfermedades neurodegenerativas con una combinación de laquinimod y fingolimod | |
| CO2022016537A2 (es) | Vacuna inactivada para sars-cov-2 y preparación de la misma | |
| BR112018072298A2 (pt) | tratamento de infecções pelo vírus da zika usando inibidores da alfa-glicosidase | |
| CO2024004886A2 (es) | Composiciones de gel inmunógenas | |
| CO2022007006A2 (es) | Vacuna triple contra avibacterium paragallinarum y el virus de la encefalomielitis aviar y el virus de la viruela aviar | |
| MX2012002630A (es) | Regimen de inmunizacion por sensibilizacion-refuerzo heterologa contra el virus de la lengua azul. |